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1. INTRODUCTION
The emergence of the Severe Respiratory Syndrome Coronavirus 2 
(SARS-CoV-2) had caused the COVID-19 pandemic and had 
resulted in signification medical challenges and societal interrup-
tion [1]. The clinical spectrum of COVID-19 is variable and ranges 
from asymptomatic, mildly symptomatic, moderately severe and 
severe disease [2–6]. About 5% of the patients would require 
Intensive Care Unit (ICU) admission, mechanical ventilation, and 
may succumbed into their illness. The reported case fatality rate of 
COVID-19 is variable between countries and localities [7,8]. There 
had been few studies of the clinical characteristics of COVID-19 in 
Saudi Arabia and these studies showed similar clinical characteris-
tics to those reported in the literature [4–6,8,9]. Similar to the 
Middle East respiratory syndrome coronavirus [10], the clinical 
course of COVID-19 may go through an initial viral replicative 
phase followed by an intense inflammatory response [11]. This 
immune response may subsequently lead to acute respiratory dis-
tress syndrome, and may be associated with a cytokine storm [12]. 
Cytokine storm is thought to be secondary to hyper-production of 
cytokines including IL-6 and may increase the patient’s risk of 
death [13,14]. Therapeutic options for COVID-19 had been limited 
despite an extensive initial evaluation of multiple medications 
including hydroxychloroquine, ritonavir, remdesivir, and cortico-
steroids. Cytokine storm is of particular importance due to the lim-
ited therapeutic options. In addition, clinical diagnosis is a common 
theme and biomarkers such as IL-6 is not commonly available at 
many healthcare settings [15]. Acute inflammatory markers such as 
C-Reactive Protein (CRP) and ESR are not specific for cytokine 
storm. However, these markers might aid in the monitoring of 
response to therapy. In an attempt to enhance therapy for cytokines 
storm, Tocilizumab (TCZ) has been suggested as a therapeutic 
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A B S T R AC T
Background: The clinical spectrum of COVID-19 is variable and ranges from asymptomatic, mildly symptomatic, moderately 
severe and severe disease. A small proportion might develop severe disease and may have cytokine storm. One of the therapeutic 
options to treat such cases is Tocilizumab (TCZ). In this study, we present cases of severe COVID-19 treated with TCZ and 
glucocorticoids and discuss the treatment responses.
Methods: This is a retrospective observational study of severe COVID-19 cases treated with TCZ and glucocorticoids. The case 
series examined the characteristics and outcome of those patients.
Results: This study included 40 Severe Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) confirmed patients who received 
TCZ and glucocorticoids. The mean age of the included patients was 57.55 (±Standard deviation 12.86) years. There were 34 
(85%) males, 19 (47.5%) were obese (BMI >30), 13 (32.5%) over weight, and five (12.5%) normal weight. The mean days from 
positive SARS-CoV-2 PCR test to admission was 1.641 (±3.2) days. Of the patients, 18 (45%) had diabetes mellitus, 14 (35%) 
had hypertension. The mean days from hospital admission to ICU was 1.8 (±2.6), 20 (50%) required mechanical ventilation, 39 
(97.5%) had received prone position, seven (17.5%) had renal replacement therapy, 13 (32.5%) required inotropes, four (10%) 
had plasmapheresis, one (2.5%) had intravenous immunoglobulin, all patients received steroid therapy, and the majority 31 
(77.5%) did not receive any anti-viral therapy. Of all the patients, six (15%) died, 28 (70%) were discharged and six (15%) were 
still in hospital.
Conclusion: The overall mortality rate was lower than those cited in meta-analysis. As our understanding of the COVID-19 
continues, the approach and therapeutics are also evolving.
© 2021 The Authors. Published by Atlantis Press International B.V. 
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option for the disease and had been used in clinical practice for 
such cases [15–19]. TCZ is a humanized monoclonal antibody 
against IL-6 receptors and thus will inhibit the action of IL-6 [20]. 
However, the exact mechanism of action of TCZ in the treatment 
of cytokine storm is not well known. In this retrospective observa-
tional study, we present cases of severe COVID-19 treated with 
TCZ and glucocorticoids and discuss the treatment responses.
2. MATERIALS AND METHODS
This is a retrospective observational study of severe COVID-19 
cases treated with TCZ and glucocorticoids. The patients were 
admitted and treated at King Fahad Military Medical Complex, 
Dhahran, Saudi Arabia. The patients received TCZ if they met 
the severe or critical case criteria [21]. The diagnosis of severity 
was based on (1) respiratory rate >30 breaths/min (2) O2 satura-
tion <93% on room air (3) a ratio of PaO2 to FiO2 of <300 mmHg. 
The diagnosis of critical cases was based on (1) respiratory failure 
requiring mechanical ventilation (2) the presence of hemodynamic 
shock (3) multi-organ failure and (4) ICU admission [21]. The 
diagnosis of SARS-CoV-2 was based on a positive Real-time (RT)-
PCR assay for SARS-CoV-2 in nasopharyngeal swabs [4,5,8,9,22].
We collected, in a standardized excel form, the following vari-
ables: demographics, laboratory data, therapeutic agents being 
used and outcome. The Institutional Review Board of the King 
Fahad Military Medical Complex approved the study (AFHER-
IRB-2020-030).
2.1. Statistical Analysis
The clinical and demographic characteristics of patients and labo-
ratory variables were compared on days 1, 2, 7 and 14 of TCZ and 
steroid therapy using Minitab. The mean and Standard Deviation 
(SD) of neutrophil count, lymphocyte count, platelet count, CRP, 
d-dimer, Lactate Dehydrogenase (LDH), serum ferritin level, serum 
procalcitonin level, and serum lactate level were compared on the 
specified days using analysis of variance. A significant p-value for 
the difference was considered when p was <0.05.
3. RESULTS
This study included 40 confirmed COVID-19 patients who were 
treated with TCZ (Roche Pharma “Schweiz” Ltd; B2084B21) and 
corticosteroid. The first TCZ dose was based on body weight and 
was 4–8 mg/kg. The mean age of the included patients was 57.5 
(±SD 12.8) years. There were 34 (85%) males and the majority were 
Saudis (N = 37, 82.5%). Of all the patients, 19 (47.5%) were obese 
(BMI > 30), 13 (32.5%) were overweight, and five (12.5%) had 
normal BMI (BMI 18.5–24.9). The mean days from positive SARS-
CoV-2 PCR test to admission was 1.6 (±3.2) days. Of the patients, 
18 (45%) had diabetes mellitus, 14 (35%) had hypertension. On 
admission, 18 (45%) were febrile with temperature of 38°C, and 26 
(65%) were receiving oxygen due to hypoxia. The mean days from 
hospital admission to ICU admission was 1.8 (±SD2.6), 20 (50%) 
required mechanical ventilation, 39 (97.5%) had received prone 
position, seven (17.5%) had renal replacement therapy, 13 (32.5%) 
required inotropes, four (10%) had plasmapheresis, one (2.5%) had 
Figure 1 | WBC count (mean and 95% CI) on different days after the start 
of tocilizumab on different days (D1, D2, D7, and D14).
Figure 2 | Neutrophil count (mean and 95% CI) on different days after the 
start of tocilizumab on different days (D1, D2, D7, and D14).
intravenous immunoglobulin, all patients received corticosteroid 
therapy, and the majority (77.5%) did not receive any anti-viral 
therapy. Those who received anti-viral therapy were treated with 
favipiravir (n = 3), lopinavir/ritonavir (n = 2), lopinavir/ritonavir 
and Ribavirin (n = 2), or tenofovir (n = 2). The most frequently 
prescribed corticosteroid was dexamethasone 6 mg daily (n = 24; 
60%) and the other patients received methylprednisone in variable 
doses (from 20 to 125 mg). The mean duration from admission to 
TCZ therapy was 2.8 (±SD 2) days. Of all the patients, six (15%) 
patients died, 28 (70%) patients were discharged and the others 
were still in hospital.
Analysis of variance of the laboratory tests showed a significant 
difference in the mean WBC on day 14 (mean = 11.04, ±SD 4.5) 
compared to day 2 (mean 7.8, ±SD 3.2) and to day 1 (mean 6.4, 
±SD 3.2) (p < 0.0001) (Figure 1). Neutrophil counts were signifi-
cantly higher on day 14 compared to other days (Figure 2). Platelet 
count was significantly higher on day 7 and day 14 compared to 
day 1 (Figure 3). CRP level was significantly lower on days 7 and 
14 compared to day 1 and day 2 (Figure 4). However, there was no 
difference in the mean (±SD) of lymphocyte count, d-dimer, LDH, 
ferritin, procalcitonin, and lactate in the different days.
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Figure 3 | Platelet count (mean and 95% CI) on different days after the 
start of tocilizumab on different days (D1, D2, D7, and D14).
Figure 4 | CRP level (mean and 95% CI) on different days after the start of 
tocilizumab on different days (D1, D2, D7, and D14).
4. DISCUSSION
In this retrospective study, we presented the outcome of 40 patients 
treated with TCZ and corticosteroid. The case fatality rate in this 
study was 10% and of the total cases 60% were discharged from the 
hospital. TCZ had been used as a therapy for patients presumed to 
have cytokine storm. The mean age of the included patients was 
57.5 (±SD 12.8) years. In an observational study of TCZ therapy of 
COVID-19, the median age was 69 years [23]. In previous studies 
from Saudi Arabia, the reported mean age was 36–38 years [5,24] 
and a median age 44 years in another study [25]. In this study, 18 
(45%) had diabetes mellitus, 14 (35%) had hypertension. Similarly, 
a previous study showed hypertension in 47% and diabetes in 
16% [23]. The cited rates of the presence of comorbidities varies 
between 32% and 93% in different studies [12,26].
The included patients received TCZ within was 2.8 (±2) days. 
However, the mean time from development of symptoms to receiv-
ing TCZ was approximately 10 days [17,27]. It had been argued that 
it is not easy to put a definite time for the initiation of TCZ as the 
clinical course of COVID-19 is variable [14].
The included patients had high inflammatory markers such as fer-
ritin and CRP levels indicating the role of inflammatory markers 
in the pathophysiology of hypoxia [2,26,28–30]. Our patients had 
significant increase in the CRP at the initiation of therapy indicat-
ing a severe disease [31]. Following therapy, we observed reduction 
on the CRP on days 7 and 14. Similarly in a randomized clinical 
trial of TCZ, there was a reduction in CRP over time in the TCZ 
arm [32]. Another study showed that CRP levels decreased from 95 
to 14 mg/L (p < 0.001) [31]. We had not seen a significant change 
in lymphocyte count overtime. One study showed that lymphocyte 
counts increased to 1000/µL from 900/µL (p = 0.036) [31].
The case fatality rate in this study was 15% and was different from 
23.2% in a previous study [23] and that study used multiple ther-
apeutics and only cyclosporin was shown to have a significant 
reduction in mortality [23]. In the BACC Bay trial, a randomized 
controlled study, there was no advantage of using TCZ on the rate of 
intubation or death with 95% confidence interval of 0.38–1.81 for 
these outcomes in the TCZ group compared to the placebo group 
[28]. In a large cohort study, 125 (28.9%) of 433 patient treated with 
tocilizumab died compared with a death rate of 37.1% in those 
who did not receive tocilizumab (risk difference, 9.6%) [33]. An 
additional randomized control trial of patients with COVID-19 
requiring oxygen outside ICU, TCZ did not have an effect on day 
28 mortality rate [32]. In a case control study, a single 400 mg TCZ 
dose increased the survival in patients with COVID-19 not requir-
ing mechanical ventilation [34]. The lethality rate was reduced with 
TCZ in patients not requiring mechanical ventilation [35].
The observed case fatality rate in the current study was 15% and was 
lower than those reported previously. One of the possible explana-
tions is that 15% of the patients were still in hospital at the time of the 
reporting. In a study from Saudi Arabia, the overall 30-day mortality 
was 31.1% in patients who received TCZ and steroid [36]. Another 
possible explanation is the difference in the time of reporting cases 
in different studies. In a systematic review that included 10,150 
COVID-19 patients who were admitted to ICUs from 24 studies 
across Europe, Asia, and North America, the mortality rate dropped 
from 60% at the end of March 2020 to 42% at the end of May 2020 
[37]. A third possible explanation is variability in therapies across dif-
ferent countries and centers. In a meta-analysis of 15 studies, the ICU 
crude mortality rate was 25.7% [38]. Another possible factor is the 
use of steroid as it had been shown to decrease case fatality rate from 
25.7% in standard therapy to 22.9% in the dexamethasone group [39].
This study is a case series of COVID-19 treated with corticoste-
roid and TCZ. As such the study has few limitations. One of the 
limitations is the small sample size of 90 cases. In addition, this is 
a retrospective study with the lack of a concurrent control arm and 
a control group to elucidate the contribution of TCZ to the therapy 
of severe COVID-19 cases.
In conclusion, we described the presentation and outcome of hos-
pitalized severe COVID-19 patients treated with both TCZ and 
corticosteroid. The overall case fatality rate was lower than those 
cited in meta-analysis. However, there are multiple explanations for 
such differences. As our understanding of SARS-CoV-2 infection 
continues, the approach and therapeutics are also evolving. In a 
recent commentary, it was indicated that several studies reported 
remarkable results with TCZ and it is advisable to have additional 
studies from additional clinical trials [14].
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